BGB-16673-304: A study to evaluate the safety and efficacy of BGB-16673 compared to pirtobrutinib in adults with relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma

This trial aims to see how safe and effective the treatment BGB-16673 is in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06973187

Trial aim and background

The aim of this trial is to compare the effectiveness and safety of the treatment BGB-16673 in people with CLL/SLL compared to treatment with pirtobrutinib.

Who can enter

Adults with CLL or SLL who have previously received treatment with a BTKi might be eligible for this trial.

Locations

Recruitment is taking place at the following UK locations:

  • University Hospitals Sussex NHS Foundation Trust, Brighton
  • Kent and Canterbury Hospital, Canterbury
  • Salisbury Foundation Trust, Salisbury

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT06973187

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.